Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system

Boyett, Deborah; Kinslow, Connor J.; Bruce, Samuel S.; Sonabend, Adam M.; Rae, Ali I.; McKhann, Guy M.; Sisti, Michael B.; Bruce, Jeffrey N.; Cheng, Simon K.; Wang, Tony J. C.

doi:10.1007/s11060-019-03177-0

Cited by 15 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients' ages ranged from 29 to 68 years, with most of them being middleaged. 22 In our study, the lesions were mainly distributed in the cervical (n = 12) and thoracic segments (n = 9), which is consistent with previous results. 9,12,23 Ki-67/MIB-1, an indicator of tumor proliferation, 24 was significantly higher in grade 3 tumors than in grade 2 tumors in the present study.…”

Section: Discussionsupporting

confidence: 93%

“…Similar results were obtained in our study, and no significant difference in sex distribution was found when comparing grade 2 and 3 SFTs. The patients' ages ranged from 29 to 68 years, with most of them being middle-aged 22 . In our study, the lesions were mainly distributed in the cervical (n = 12) and thoracic segments (n = 9), which is consistent with previous results 9,12,23 .…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Solitary Fibrous Tumor of the Spine: Imaging Grading Diagnosis and Prognosis

Shen

Ren

Wang

et al. 2022

J Comput Assist Tomogr

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate the imaging features and prognosis of spinal solitary fibrous tumors (SFTs) of different pathological grades.MethodsThe clinical features, computed tomography and magnetic resonance (MR) images, and follow-up data of 23 patients with SFTs were reviewed. The patients were divided into 3 groups according to their pathological manifestations: grade 1 (n = 3), grade 2 (n = 14), and grade 3 (n = 6). The following imaging features were recorded: location, computed tomography density/MR intensity, enhancement pattern, dural tail sign, adjacent bone remodeling, lobulation, and tumor size. The immunohistochemical (Ki-67/MIB-1) levels were also investigated. All parameters were statistically analyzed between grade 2 and 3 tumors.ResultsThe Ki-67/MIB-1 index was markedly higher in grade 3 tumors than in grade 2 tumors (P < 0.001). All grade 1 lesions appeared hypointense on T2-weighted image, whereas grade 2 and 3 lesions appeared isointense or mildly hyperintense. There were significant differences in enhancement type and osteolytic bony destruction between grade 2 and 3 tumors (P < 0.05). However, no marked differences were found in the distribution of age, sex, location, MR signal, degree of enhancement, compressive bony absorption, dural tail sign, or maximum vertical/traverse diameter ratio. Malignant progression occurred less frequently in patients with grade 2 tumors than in those with grade 3 tumors, but the difference was not statistically significant.ConclusionsDifferent grades of spinal SFTs have different degrees of proliferation and imaging features, especially grade 3 tumors, which show a heterogeneous enhancement pattern, osteolytic bony destruction, and a higher possibility of recurrence and metastasis.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 92%

Solitary Fibrous Tumor of the Spine: Imaging Grading Diagnosis and Prognosis

Shen

Ren

Wang

et al. 2022

J Comput Assist Tomogr

View full text Add to dashboard Cite

show abstract

“…Informed consent was not necessary as no identifiable data was accessed. Data were collected and analyzed as described in previous reports (19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Data Sourcementioning

confidence: 99%

Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States

May

Kinslow

Adams

et al. 2021

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: Treatment paradigms for large cell neuroendocrine carcinoma (LCNEC) of the lung are based largely upon small retrospective studies and smaller prospective trials. It is unclear if these tumors behave like non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Data are lacking with regard to the role of radiotherapy (RT). U. S. guidelines recommend that LCNEC be treated as a NSCLC.We sought to perform a cross-sectional study of LCNEC cases to understand treatment paradigms and outcomes in this disease. Methods:The Surveillance, Epidemiology and End Results database was queried for cases of stage I-III pulmonary LCNEC diagnosed 2004-2013. Treatment groups were defined as no surgery, RT alone, surgery alone, and surgery + RT. The Cox-proportional hazards regression model was used to compare overall survival and cause-specific survival (OS/CSS), stratified by AJCC 6th Staging. Factors that were significant on univariable analysis were included in multivariable analysis. Results:We identified 1,523 cases of LCNEC, with 748, 177, and 598 cases of stage I, II, and III disease, respectively. In stage I and II disease, RT was associated with improved survival for non-surgical patients, but not for those who underwent surgery. In stage I disease, the adjusted hazard ratios for OS for RT alone, surgery, and surgery + RT were 0.39, 0.21, and 0.22, respectively (P<0.001). In stage II disease, the adjusted hazard ratios for RT alone, surgery, and surgery + RT were 0.51 (P=0.15), 0.39 (P=0.004), and 0.38 (P=0.01), respectively. For patients with stage III disease, RT was associated with improved survival in surgical and non-surgical patients. The adjusted hazard ratios for RT alone, surgery, and surgery + RT were 0.49, 0.43, and 0.36, respectively (P<0.001). Conclusions:Our findings indicate that non-metastatic LCNEC may be treated as a NSCLC with respect to RT. Prospective studies are necessary to increase our understanding of optimal treatment regimens.

show abstract

“…Several previous studies explored the prognostic factors of intracranial SFT/HPC, which mostly underlined the extent of resection (EOR) as a major factor for tumor recurrence and metastasis [ 9 – 16 ]. Other factors, including WHO classification [ 9 , 15 ], adjuvant therapy [ 16 – 20 ], age [ 21 , 22 ], location, and size of tumor [ 23 ] had also been reported that related to patient’s progression-free survival (PFS) and overall survival (OS). However, due to the rarity of intracranial SFT/HPC, little is known about the optimal treatment and prognostic factors, and our current knowledge about SFT/HPC is mainly derived from small case series [ 4 , 9 , 11 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare mesenchymal tumors in the central nervous system with a high tendency to relapse, having a significant impact on quality of life (QoL). Due to the rarity of intracranial SFT/HPC, the prognostic factors and optimal treatment remain to be elucidated. Meanwhile, quality of life in patients with intracranial SFT/HPC is seldomly concerned. Thus, we aim to survey about the quality of life and underline some aspects demanding concern in intracranial SFT/HPC treatment through summarizing our case series in recent ten years. Methods Patients with intracranial SFT/HPC who underwent surgical resection from January 2009 to June 2019 were included in the study. Clinical features, such as age, gender, and resection extent, were collected. The EuroQol Five Dimensions Questionnaire (EQ-5D) was used to assess the patients’ quality of life (QoL). Prognosis factors related to progression-free survival (PFS) and overall survival (OS) were also evaluated. Results Thirty-six patients with a mean follow-up period of 61.6 months (range 13–123 months) were included in this study. Sixteen (44.4%) patients achieved gross total resection (GTR). Fourteen patients (38.9%) with tumor progression experienced adjuvant radiotherapy (11.1%) or Gamma Knife surgery (GKS, 27.8%). According to the 2016 WHO classification, there were 6 (16.7%) grade I SFT/HPC, 11 (30.5%) grade II SFT/HPC, and 19 (52.8%) grade III SFT/HPC. The PFS and OS were 29 months (range 4–96 months) and 38 months (range 4–125 months). The median EQ5D-3 L tariff with or without progression was 0.617 (95% CI 0.470–0.756) and 0.939 (95% CI 0.772–0.977) respectively. Gross total resection (GTR, p = 0.024) and grade I SFT/HPC (p = 0.017) were significantly associated with longer PFS. In multivariate analysis, GTR (HR 0.378, 95% CI 0.154–0.927) and adjuvant therapy (HR 0.336, 95% CI 0.118–0.956) result in significantly longer PFS in patients with SFT/HPC. Conclusions Patients underwent GTR and adjuvant therapy had longer PFS. Similarly, patients with lower WHO grade had relatively longer PFS. Therefore, GTR is advocated for the treatment of SFT/HPC. And adjuvant therapy such as GKS could be an alternative treatment for patients who underwent STR or with tumor progression. Further, the QoL decreased in patients with tumor progression and metastasis, and more attention is demanded to the QoL of intracranial SFT/HPC patients.

show abstract

Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system

Cited by 15 publications

References 58 publications

Solitary Fibrous Tumor of the Spine: Imaging Grading Diagnosis and Prognosis

Solitary Fibrous Tumor of the Spine: Imaging Grading Diagnosis and Prognosis

Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States

Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis

Contact Info

Product

Resources

About